Global pharma major Lupin Limited and nonprofit drug developer TB Alliance have announced a strategic collaboration to advance the clinical development and commercialization of Telacebec (Q203), an investigational drug for tuberculosis, leprosy, and Buruli ulcer. The partnership combines TB Alliance’s research expertise with Lupin’s manufacturing and regulatory capabilities to accelerate access.
Show moreStay Ahead – Explore Now! WOW STORY OF THE DAY: Theobroma’s Sweet Success: How India’s Brownie Brand Baked Its Way to Big Profits
Copyright 2024 WOWNEWS 24x7. All rights reserved. The WOWNEWS 24x7 is not responsible for the content of external sites. Read about our approach to external linking.
Powered By Just Imagine
